Clinical Scorecard: A novel nomogram utilizing tumor burden for assessing synchronous esophageal and gastric cancers: creation and external validation

At a Glance

Key Highlights

• Development of a prognostic nomogram integrating age, treatment modality, and Combined EG_Stage
• External validation showed a C-index of 0.681 for overall survival
• Median overall survival was significantly different between risk stratification groups (41 vs 22 months)
• Nomogram aims to improve individualized prognostic evaluation for SEGC
• Limited sample size warrants cautious interpretation of results

Guideline-Based Recommendations

Diagnosis

• Pathologically distinct primary malignancies diagnosed within a six-month interval

Management

• Multimodal treatment options including surgery or endoscopic therapy

Monitoring & Follow-up

• Survival follow-up and assessment of treatment outcomes

Risks

• Prognostic uncertainty due to clinical heterogeneity of SEGC

Patient & Prescribing Data

Patients diagnosed with synchronous esophageal and gastric cancers

Incorporation of treatment modality as a prognostic indicator

Clinical Best Practices

• Utilize the Combined EG_Stage framework for assessing tumor burden
• Consider age and treatment modality in prognostic evaluations
• Engage in multidisciplinary management for SEGC patients

Related Resources & Content

• Surveillance, Epidemiology, and End Results (SEER) database